Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Bank of America Merrill
View HTML
Toggle Summary ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Trastuzumab emtansine (T-DM1) progress includes achievement of progression-free survival (PFS) endpoint in lead Phase III trial for HER2+ metastatic breast cancer. Data from this trial and the Phase II safety trial in (neo)adjuvant setting submitted to ASCO for presentation.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 27, 2012 , to discuss ImmunoGen's financial results
View HTML
Toggle Summary ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853
Potential new therapeutic for ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors which over-express folate receptor 1 (FOLR1). Achievement of active IND for IMGN853 closely follows start of patient dosing with IMGN529 and initiation of Phase II testing with IMGN901.
View HTML
Toggle Summary ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound
— First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that it will host a conference call at 8:00 am ET on Friday, March 30, 2012 to discuss the two releases issued by the Company earlier today: The
View HTML
Toggle Summary ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned interim analysis to enable early decisions on next steps to advancement. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
Roche has announced lead Phase III trial with trastuzumab emtansine has met progression-free survival endpoint Plans to apply for marketing approval of trastuzumab emtansine in US and Europe Study data being submitted for presentation at major medical meeting WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Cowen 32 nd Annual Health Care Conference at 10:40 am ET on March 7, 2012 will be webcast live.
View HTML